Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade Glioma
Phase of Trial: Phase IV
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Carmustine polifeprosan 20 wafer (Primary)
- Indications Glioma
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 18 Apr 2017 Status changed from active, no longer recruiting to completed.
- 23 Dec 2016 Planned End Date changed from 1 Mar 2017 to 1 Feb 2017.
- 23 Dec 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2016.